Lipidor Ab Cash Flow Conversion Efficiency
Lipidor Ab cash flow conversion efficiency. Based on the latest financial reports, Lipidor Ab (LIPI) has a cash flow conversion efficiency ratio of -0.130x as of June 2024. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-2.11 Million ≈ $-227.39K USD) by net assets (Skr16.29 Million ≈ $1.75 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Lipidor Ab (2016–2024)
Cash flow conversion efficiency of Lipidor Ab from 2016 to 2024. This chart illustrates how Lipidor Ab's cash flow conversion efficiency has evolved over time, based on yearly financial data. View LIPI live share price for real-time trading data and today's change.
Lipidor Ab Cash Flow Conversion Ratio Explained
Lipidor Ab cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Lipidor Ab Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lipidor Ab ranked by their cash flow conversion efficiency. Also see Lipidor Ab (LIPI) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PERFORMANCE SHIPP.
F:DS2
|
0.030x |
|
Catenon S.A
MC:COM
|
0.241x |
|
Control Bionics Ltd
AU:CBL
|
-0.559x |
|
Smart Concrete Public Company Limited
BK:SMART
|
0.028x |
|
Bakrie Sumatera Plantations
JK:UNSP
|
-0.021x |
|
Blossom M&C Co. Ltd
KQ:263920
|
-0.023x |
|
Wonlim Corp.
KO:005820
|
-0.016x |
|
Smithson Investment Trust PLC
LSE:SSON
|
0.000x |
Annual Cash Flow Conversion Efficiency for Lipidor Ab (2016–2024)
The table below shows the annual cash flow conversion efficiency of Lipidor Ab from 2016 to 2024. Review Lipidor Ab free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr7.72 Million ≈ $831.01K |
Skr-16.08 Million ≈ $-1.73 Million |
-2.082x | -216.42% |
| 2023-12-31 | Skr-9.34 Million ≈ $-1.01 Million |
Skr-16.70 Million ≈ $-1.80 Million |
1.789x | +109.84% |
| 2022-12-31 | Skr2.15 Million ≈ $230.94K |
Skr-39.00 Million ≈ $-4.20 Million |
-18.174x | -5811.04% |
| 2021-12-31 | Skr43.52 Million ≈ $4.68 Million |
Skr-13.38 Million ≈ $-1.44 Million |
-0.307x | -28.15% |
| 2020-12-31 | Skr63.66 Million ≈ $6.85 Million |
Skr-15.27 Million ≈ $-1.64 Million |
-0.240x | +56.67% |
| 2019-12-31 | Skr26.83 Million ≈ $2.89 Million |
Skr-14.85 Million ≈ $-1.60 Million |
-0.554x | -185.21% |
| 2018-12-31 | Skr14.45 Million ≈ $1.55 Million |
Skr-2.81 Million ≈ $-301.86K |
-0.194x | +81.58% |
| 2017-12-31 | Skr3.48 Million ≈ $374.18K |
Skr-3.66 Million ≈ $-394.30K |
-1.054x | +76.02% |
| 2016-12-31 | Skr833.68K ≈ $89.72K |
Skr-3.66 Million ≈ $-394.30K |
-4.395x | -- |
About Lipidor Ab
Lipidor AB (publ), a pharmaceutical development company, engages in the development of drugs for the treatment of psoriasis, acne vulgaris, bacterial skin infections, and atopic dermatitis. The company develops AKP-01, which is in Phase III for the treatment of psoriasis; and preclinical stage products, such as AKP-02 for psoriasis, AKP-03 for bacterial skin diseases, and AKP-07 for atopic dermat… Read more